All glioma articles
-
NewsServier deepens rare oncology commitment with $2.5bn Day One acquisition
The deal aligns with the biopharma company’s goal of expanding its oncology pipeline by the end of the decade.
-
NewsIpsen agrees new oncology licensing deal
The agreement relates to an innovative therapeutic for the most common paediatric brain cancer, where outside the US, there is no approved targeted treatment for certain patients.
-
NewsNICE recommends Novartis precision brain cancer treatment
An “innovative, life-extending treatment” for BRAF V600E mutation-positive glioma has been recommended for certain young people on the NHS.